This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Teva, Actavis, others file replies for dismissing US claims over generic drugs

( February 20, 2025, 17:38 GMT | Official Statement) -- MLex Summary: Teva Pharmaceuticals, Actavis, Heritage Pharmaceuticals and other generic drug companies filed replies in support of their motions to dismiss US antitrust claims filed by self-funded direct-action plaintiffs. They said the plaintiffs don't attempt to provide any justification for their decision to delay nearly a decade before filing claims in 2024 for injuries resulting from the purported overarching conspiracy that, according to the first amended complaint, began in 2009.  See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login